Literature DB >> 9402350

Antimicrobial treatment of Helicobacter pylori infection.

C S Goodwin1.   

Abstract

Helicobacter pylori is susceptible to many antimicrobials, but clinically only a few are effective. Two antimicrobials with bismuth or ranitidine or a proton pump inhibitor such as omeprazole are required to achieve a cure rate of >90% and to avoid resistance, which occurs when clarithromycin or metronidazole is the single antimicrobial used. Bismuth plus metronidazole and tetracycline is effective but causes more side effects than does treatment with omeprazole, amoxicillin, and clarithromycin; metronidazole can replace clarithromycin. To ensure a high cure rate, treatment is required for 10 days, but 7-day regimens have sometimes been as successful. A course of ranitidine bismuth citrate for 28 days, given with clarithromycin for the first 14 days, cures 80%-85% of patients, but given with amoxicillin it cures only 74%. In developing countries resistance to metronidazole can reach 95%. An inexpensive regimen is bismuth subsalicylate (two tablets) plus furazolidone (100 mg), four times daily for 4 weeks; however, as this yields a cure rate of only 72%, this regimen is not truly cost-effective.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402350     DOI: 10.1086/516078

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice.

Authors:  P J Jenks; R L Ferrero; J Tankovic; J M Thiberge; A Labigne
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 2.  Pharmacological, therapeutic and toxicological properties of furazolidone: some recent research.

Authors:  B H Ali
Journal:  Vet Res Commun       Date:  1999-10       Impact factor: 2.459

3.  Antimicrobial activity of Sapindus mukorossi and Rheum emodi extracts against H pylori: In vitro and in vivo studies.

Authors:  Mohammed Ibrahim; Aleem-A Khan; Santosh-K Tiwari; Mohammed-Aejaz Habeeb; M-N Khaja; C-M Habibullah
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

4.  Characterization of an In vitro-selected amoxicillin-resistant strain of Helicobacter pylori.

Authors:  C R DeLoney; N L Schiller
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

5.  PCR-based diagnosis of Helicobacter pylori infection and real-time determination of clarithromycin resistance directly from human gastric biopsy samples.

Authors:  S A Chisholm; R J Owen; E L Teare; S Saverymuttu
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

6.  Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori.

Authors:  M M Gerrits; D Schuijffel; A A van Zwet; E J Kuipers; C M J E Vandenbroucke-Grauls; J G Kusters
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.